InvestSMART

Immuron Limited (ASX: IMC) - Announcements

- Current share price for IMC : $0.045

ASX company news and announcements for Immuron Limited (IMC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Immuron Limited (IMC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Immuron Limited (IMC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Immuron Limited (IMC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$15 European Patent Gramted for Nash Treatment 11 Jul 2018 11:54AM $0.330 $0.045 fallen by 86.36%
$15 Resignation of Joint Company Secretary 29 Jun 2018 6:41PM $0.340 $0.045 fallen by 86.76%
$15 Immuron Announces Board Appointment 26 Jun 2018 9:55AM $0.360 $0.045 fallen by 87.50%
$15 Trading halt request 25 Jun 2018 11:25AM $0.360 $0.045 fallen by 87.50%
$15 Trading Halt 25 Jun 2018 10:58AM $0.360 $0.045 fallen by 87.50%
$15 IMC Preclinical Study Reports Reduction in Colitis Symptoms 8 May 2018 11:05AM $0.295 $0.045 fallen by 84.75%
$15 Immuron CEO to Present at RedChip Global Online Growth Conf 24 Apr 2018 8:38AM $0.310 $0.045 fallen by 85.48%
$15 Travelan Sales Continue to Soar in Third Quarter of FY2018 23 Apr 2018 11:09AM $0.330 $0.045 fallen by 86.36%
$15 Becoming a substantial holder 20 Mar 2018 9:57AM $0.390 $0.045 fallen by 88.46%
$15 ASX Documentation Request - Reduction of Capital (Nov 2017) 19 Mar 2018 3:22PM $0.395 $0.045 fallen by 88.61%
$15 Form 604 - Change in Substantial Shareholding (Grandlodge) 19 Mar 2018 11:24AM $0.400 $0.045 fallen by 88.75%
$15 Appendix 3B & 708A Notice (Placement to US Fund Allotment) 16 Mar 2018 2:18PM $0.410 $0.045 fallen by 89.02%
$15 Immuron Announces A$5.1M Private Placement to U.S. Fund 14 Mar 2018 9:03AM $0.470 $0.045 fallen by 90.43%
$15 Immuron Progresses Discussions with Institutional Funds 13 Mar 2018 11:15AM $0.390 $0.045 fallen by 88.46%
$15 Immuron Commences US Non-Deal Institutional Investor Roadshw 13 Mar 2018 9:53AM $0.390 $0.045 fallen by 88.46%
$15 Trading Halt Request 12 Mar 2018 9:45AM $0.390 $0.045 fallen by 88.46%
$15 Trading Halt 12 Mar 2018 9:45AM $0.390 $0.045 fallen by 88.46%
$15 Immuron Reports Positive Results in NASH Clinical Trial 8 Mar 2018 9:52AM $0.285 $0.045 fallen by 84.21%
$15 Correction to False and Misleading News Release 7 Mar 2018 2:17PM $0.285 $0.045 fallen by 84.21%
$15 Trading Halt 7 Mar 2018 9:20AM $0.285 $0.045 fallen by 84.21%
$15 Appendix 4D - Half Year Financial Report - 31 Dec 2017 28 Feb 2018 8:14AM $0.300 $0.045 fallen by 85%
$15 Travelan Revenue Grows Significantly in US and Australia 16 Feb 2018 10:41AM $0.255 $0.045 fallen by 82.35%
$15 IMC Enrols First Patients in IMM529 C. Difficile Study 31 Jan 2018 12:18PM $0.270 $0.045 fallen by 83.33%
$15 US Defence Depart Report-Travelan Targets Priority Pathogens 30 Jan 2018 8:22AM $0.230 $0.045 fallen by 80.43%
$15 Immuron to Receive $2.16M R&D Tax Concession Cash Refund 23 Jan 2018 9:46AM $0.230 $0.045 fallen by 80.43%

501 - 525 of 783 results

Page 21 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.